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KNOWLEDGE SUMMARY 
 
 
 
 
 
 
Question 
Do anxious dogs administered alpha-casozepine show reduced signs of anxiety compared with dogs not 
administered alpha-casozepine? 
 
Clinical Scenario  
The veterinary team are reviewing the products that they keep within the practice for use in supporting 
clients whose dogs are anxious for various reasons. They realise that they have never examined the evidence 
for the use of alpha-casozepine in relation to canine anxiety. However, they have been widely recommending 
products that contain it, and have had mixed reports back from clients who have used it, so are curious about 
its efficacy. Thus, they decide to find out how strong the research evidence base is for this biomolecule. 
 
The Evidence  
The Three peer reviewed papers were identified that either partially or fully addressed the PICO. Two of 
these studies (Palestrini et al., 2010; Kato et al., 2012) investigated the use of diets with added alpha-
casozepine, though, in the Kato et al. (2012) study the diet was also supplemented with another compound 
(tryptophan) thought to have anxiolytic properties. The remaining study (Beata et al., 2007) investigated the 
use of a daily capsule of alpha-casozepine. The two studies focused on dietary interventions (Palestrini et al, 
2010; Kato et al., 2012) used a placebo-controlled study design, whereas Beata et al. (2007) compared alpha-
casozepine to another intervention (selegiline) that was already used commercially as an anxiolytic. 
 
There is no evidence that alpha-casozepine has any effect on canine anxiety in the short term (e.g. when 
exposed to fireworks or another short acting stressor) or when administered a few minutes to a few days 
before exposure to potential stressor. All of the studies focus on the potential anxiety-reducing effects of 
alpha-casozepine when administered in the medium to long term. There was some evidence that alpha-
casozepine may reduce anxiety as, where effects exist, the direction of effect is always a reduction in the 
level of whatever parameter was used to measure anxiety. However, the evidence available is low quality. 
Despite being clinical trials, experimental design and / or data handling was weak, with confounding variables 
affecting interpretation of the findings. There is a need for better quality research that specifically 
investigates the use of alpha-casozepine as an anxiolytic in the scenarios that practices would commonly 
promote its use for. 
 
 
Clinical bottom line  
There is currently no evidence to show that alpha-casozepine is effective as an anxiolytic when 
administered to dogs shortly (minutes to a few days) before exposure to an anxiety provoking stressor. 
There is limited and weak evidence to suggest that it may have a role to play in reducing anxiety in dogs 
over the medium to longer term but the available evidence is of low quality and / or high risk of bias, with 
confounding variables providing alternative explanations for the findings. More research is needed in this 
area. 
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Summary of the evidence 
 
1. Palestrini (2010) 
Population: Healthy young adult female laboratory-based beagles  
Sample size:  32 dogs: 
Anxious dogs: n = 16 (later reduced to 14, possibly 131), split 
between two groups (experimental diet versus control diet).  
Non-anxious dogs: n = 16, split between two groups. 1 group (n = 8) 
received the experimental diet; 1 group received the control diet (n 
= 8). 
 
1 The authors reporting of this aspect is weak and they report 
eliminating 3 anxious dogs, but then claim later in the same section 
to have reduced the anxious treatment group from 16 dogs to 14 
dogs. They do not report how this affected numbers of dogs in each 
group, therefore, the minimum sample size for one of the diet 
groups could be as low as 6 (if 2 are missing) or 5 (if 3 are missing). 
Intervention details: Dogs were split into four groups: 
1. Anxious dogs fed the control diet 
2. Anxious dogs fed the experimental diet 
3. Non-anxious dogs fed the control diet 
4. Non-anxious dogs fed the experimental diet 
 
The two diet treatments compared were: 
1. Experimental diet: a complete dry dog food that was coated 
with caseinate hydrolysate (CH) (the milk component 
containing alpha-casozepine). The authors do not report the 
inclusion rate of CH. 
2. Control diet: the same diet as the experimental diet but 
without the CH. 
 
 
Researchers were blinded to which dogs were receiving which 
treatment. 
 
Experimental timeline: 
Forty dogs were assessed for anxiety and either included in the study 
(n = 32) or rejected (n = 8).  
Anxiety assessment used two methods:  
1. The Evaluation Scale of Anxiety, and  
2. The Reactivity Evaluation Form (REF) (more details below).  
Based on the combined scores, dogs were ranked for level of 
anxiety. The top 16 dogs were then assigned to the anxious group 
and the bottom 16 dogs were assigned to the non-anxious group. 
The intermediary 8 dogs were not used.  
 
Within group, the dogs were paired-housed such that dogs with the 
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most similar scores were housed together (e.g. the most anxious dog 
was housed with the second most anxious dog, etc).  
 
A randomised block design was then used to allocate diet treatments 
to the dogs. Dogs were blocked according to whether they were 
anxious or non-anxious (based on the anxiety assessment methods 
outlined above), and then the 8 pairs of dogs within each block were 
randomly allocated to receive one of the two diet treatments. Both 
dogs within the pair received the same diet. 
The dogs included were allocated as described above and then pair-
housed. Dogs were introduced to their new kennel mate and given 3 
days to adjust to this. Then, the study commenced. 
 
The study lasted either 68 or 69 days (not clear enough to say for 
certain). 
1. Baseline period (6 days): baseline parameters were 
measured for serum cortisol, serum lysozyme, the 
neutrophil:lymphocyte ratio, and mean heart rate. Heart 
rate was measured telemetrically using a heart rate monitor 
strapped to the dog’s chest and recorded at 5 second 
intervals. Dogs were fed their normal diet during this period. 
 
2. Initial evaluation phase (T1) (2 or 3 days, this is unclear from 
the paper*): on the first day, the REF was completed and a 
blood sample taken. On day two, the mean heart rate was 
determined for ten minutes while the dogs were video 
recorded for 10 minutes. This video was later viewed by an 
observer blinded to treatment and group and the frequency 
or proportion of time spent performing certain behaviours 
recorded. 
 
*In the experimental phase section of the paper, the authors report 
“after an initial 3 day evaluation phase (T1)” and “each evaluation 
(T1, T2, and T3) lasted 2 days”. 
 
3. Feeding phase 1 (28 days). Dogs were given ad libitum access 
to the food with food replenished once a day (PM), with 
both dogs in the pen fed the same diet. 
 
4. Second evaluation phase (T2, lasted 2 days). Data collection 
as documented in T1. 
 
5. Feed phase 2 (28 days). Dogs fed as documented in feeding 
phase 1. 
 
6. Third evaluation phase (T3, lasted 2 days). Data collection as 
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documented in T1. 
 
Initial assessment of anxiety (to select dogs): 
1. Evaluation scale of anxiety: a subjective assessment of 
anxiety in which dogs were observed and scored from 1 
(low) – 6 (high). 
2. REF. A two part objective behavioural assessment, 
comprising an ordinal scale of anxiety level (score 1 – 4) and 
the presence of various clinical signs of anxiety (e.g. lick lip: 
yes / no, score 1 point if yes) based on the dogs response to 
handler presence outside and inside the test pen. 
Both assessment tools were developed by the researchers of this 
study. 
 
Two experienced handlers familiar with the dogs independently 
assessed the dogs using these two assessment methods and then 
agreed the final score per dog.  
 
Study design: Randomised clinical trial 
Outcome studied: Behavioural outcome measures: 
1. REF  
2. Proportion of time spent performing various behaviours in 
the test pen over 10 minutes (exploration; locomotion, 
passive behaviour, orientated to the environment, 
scratching, oral behaviour, vocalisation, play, panting, 
grooming) 
3. Frequency of behaviours performed while in the test pen for 
10 minutes (yawning, lip – licking, elimination, drinking, 
eating) 
Physiological parameters: 
1. Heart rate  
2. Cortisol 
3. Neutrophil: lymphocyte ratio 
4.  Lysozyme 
It is not clear whether plasma or serum cortisol and lysozyme was 
measured as the authors report the terms interchangeably. 
Main findings: 
(relevant to PICO question): 
No significant differences were found between the baseline period 
data and the initial evaluation phase (T1) data, so the authors used 
T1 as their baseline data period.  
 
Behavioural outcome measures: 
1. REF: 
- At the start (T1), anxious dogs had significantly higher 
REF scores than non-anxious dogs (Mann-Whitney U 
Test, P < 0.001). 
- At the start (T1), there was no significant difference 
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between anxious dogs fed the control diet and anxious 
dogs fed the experimental diet. 
- Dogs on the experimental diet had significantly lower 
REF scores by T3 (end of the study) (Friedman Test, P < 
0.01). 
- No further formal statistical comparisons are reported. 
The figure associated with this outcome measure 
suggests that anxious dogs fed both the control and 
experiment diets always scored higher than non-anxious 
dogs fed either diet. It also suggests that there is no 
divergence in anxiety scores of non-anxious dogs fed 
either diet.  
2. Behaviour: 
- Anxious dogs and non-anxious dogs show no significant 
differences in behaviour at the start of the study (T1). 
- Anxious dogs showed less exploratory behaviour at the 
end of the study (T3) compared to the beginning (T1) 
(Friedman, P < 0.05). There was no change in level of 
exploratory behaviour between time points in anxious 
dogs fed the control diet.   
- Non-anxious dogs fed the control diet showed less 
scratching behaviour over time (Friedman, P < 0.05) 
- Anxious dogs fed the control diet showed increased lip 
licking over time (Friedman, P <0.05). 
- Anxious dogs showed a significant increase in 
orientation to the environment behaviour at T3, 
compared with T1 (Friedman, P < 0.05). 
Physiological outcome measures: 
1. Heart rate:  
- No significant effects were observed. 
2. Cortisol:  
- Remained within the normal physiological range for 
anxious and non-anxious dogs during the whole study 
- Cortisol level of anxious and non-anxious dogs did not 
differ at the start (T1).  
- Anxious dogs fed the experimental diet showed a 
significant decrease in cortisol over time (Friedman, P < 
0.05). Post hoc testing indicated that a significant 
reduction was observed between T1 and T2 (Wilcoxon, P 
< 0.05). 
- Non-anxious dogs showed a tendency to have a 
reduction in cortisol over time (Friedman, P < 0.10). 
3. Neutrophil:lymphocyte ratio: 
- A significant reduction in neutrophils (and increase in 
lymphocytes) was observed over time in anxious dogs 
(General Linear Model, P < 0.05) but not non-anxious 
dogs. Diet treatment had no effect on the ratio for 
either group of dogs. 
4. Lysozyme: 
-  No PICO relevant significant effects were observed. 
Limitations: The authors fail to report the inclusion rate for caseinate 
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hydrolysate (containing alpha-casozepine) in the diet (g/kg/Dry 
matter). 
 
The dogs were fed ad libitum during the study so the dose rate 
would have varied between dogs.  
 
Laboratory population in which the breeding life experiences of the 
dogs were homogenised and tightly controlled. This contrasts to a 
pet population and may limit extrapolation of the findings to the 
wider population of dogs. 
 
The authors undertook a discriminant analysis to retrospectively 
(after all the data was collected) eliminate dogs whose REF score did 
not accurately predict which dogs were identified as anxious 
through the Evaluation Scale of Anxiety (or vice versa, it is not clear 
which). As a consequence, 2 or 3 anxious dogs were removed. The 
authors fail to report how this affected the sample size of anxious 
dogs in the control diet and experimental diet groups respectively. 
Given the low sample sizes within each group (n = 8), this has 
implications for the interpretation of any findings or extrapolation to 
the wider population. This is compounded by the wide degree of 
variation observed (where standard deviations are reported). 
Retrospective removal of such a large proportion of the sample size 
for a group should also be questioned. 
 
The authors fail to report the measure of central tendency used to 
report the REF and cortisol data, and do not provide any measure of 
variation around this central tendency. 
 
The authors do not provide enough information to interpret the 
cortisol findings. They report that anxious and non-anxious dogs’ 
cortisol levels did not differ at T1, but do not report the findings for 
the subgroups relevant to the treatments (especially anxious dogs 
fed the experimental diet versus anxious dogs fed the control diet). 
Eyeballing the figure presented suggests that these two sub-groups 
might vary at the start and combining this data would have 
increased the variation associated with the anxious group data and 
made it more difficult to pick out significant differences. However, 
the lack of error bars makes it difficult to draw many inferences 
here.  
 
The authors report appears to use the convention of using P < 0.01 
(tendency) P < 0.05 (significant), P < 0.01 and P < 0.001 (highly 
significant). It would have been useful to see the exact P value 
associated with each finding as most appear to be P < 0.05. The way 
that they have analysed the behavioural data that they have 
reported suggests that there may have been many statistical tests 
performed and this increases the likelihood of a type 1 error (finding 
a significant finding where one does not exist).  
 
The ethogram derived behavioural data is very problematic to 
interpret: 
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- The authors report the findings using mean (± standard 
deviation) which implies the data is normally 
distributed. However, they analyse this data using non 
parametric tests (Friedman test, with post-hoc testing 
via the Wilcoxon test) which implies the data is not 
normally distributed. The error bars suggest that there 
was a large amount of variation associated with the 
performance of some behaviours. 
- The authors do not provide enough information for 
readers to be able to draw their own conclusions about 
what the behavioural data may indicate. It would have 
been useful to see the descriptive statistics reported for 
all the ethogram data, broken down by both treatment 
diet and anxiety group. 
- The authors appear to have cherry picked which 
behavioural outcome comparisons to report and key 
comparisons (e.g. between anxious dogs fed the control 
diet and anxious dogs fed the experimental diet) are 
largely missing.  
-  It is not immediately clear that changes between some 
of the behaviours in the ethogram would represent a 
change in the level of anxiety.  
2. Beata (2007) 
Population: Pet dogs with anxiety-related disorders 
 
The inclusion criteria was as follows: 
 At least 3 months old 
 Weigh between 1.5 – 42kg 
 Diagnosed with a behavioural complaint related to anxiety 
 At the first visit, the dog scored above 19 (out of a maximum 
of 45) on the Emotional Disorders Evaluation in dogs scale 
(EDED) (as used by Pageat, 1995). 
Dogs were excluded if: 
 The problem had been present for less than four weeks 
 There was any evidence that the problem was caused by 
disease, illness or injury. 
 Any psychotropic medications had been administered in the 
previous two weeks 
 If the dog scored less than 20 on the EDED scale. 
Sample size: Forty dogs started the trial, 38 dogs completed it. Two dogs died 
(one per treatment) during the study for unrelated reasons 
(accidents). 
Intervention details: Two treatments (19 dogs per treatment) were compared: 
1. Behavioural modification therapy (BMP) plus oral alpha-
casozepine (15mg/kg/24hrs) 
2. BMP plus oral selegiline hydrochloride (0.5mg/kg/24hrs) 
 
Study design: 
 Multi-centre trial that utilised 7 certified veterinary 
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behaviourists.  
 Double or triple blind (not clear which) methodology in 
which the owner, veterinary behaviourist and the 
supervisors (undefined, researchers?) were unaware which 
dog received which drug while the study was ongoing.  
 Dogs were allocated to treatments using a randomised block 
design (blocked according to a veterinary behaviourist 
treating the dog, then randomly allocated to receive a 
treatment based on a pre-defined randomisation list e.g. dog 
1 was given drug 1, dog 2 was given drug 2, and so on).  
 The BMP was tailored to the dog, diagnosis given and how 
severe this problem was. Thus, it varied between dogs but 
BMP approach did not vary systematically between the two 
treatment groups. 
 The trial lasted 57 days.  
 
Experimental timeline: 
 Day 0: Inclusion visit, owners completed the EDED 
questionnaire. Dogs that scored greater than 19 were 
included. 
 Day 14: Follow up phone call. 
 Day 28: Follow up physical visit. 
 Day 42: Follow up phone call. 
 Day 56: Follow up physical visit. 
At each contact, the owner was asked to complete the EDED scale 
again AND provide a subjective assessment of improvement on a 
scale of -10 to +10, with 0 indicating no change, and values higher 
and lower than this indicating, respectively, an improvement or 
worsening of the dog’s behavior. 
 
The EDED score was previously developed by one of the authors for 
use in investigating the ability of seligiline to reduce anxiety (Pageat, 
1995, cited  by the current authors), and uses a range of questions to 
assess the dog’s emotional state on a scale from 9-45. A score of 9-
13 is considered to be normal, 14-18 indicative of a dog with a 
phobia, with dogs that have a score that sits between 18 
-30 considered to have an anxiety-related disorder. The authors do 
not define what a score above 30 means in relation to the dog’s 
emotional state. They do not state whether this scale is validated for 
this use. 
 
Study design: Randomised clinical trial 
Outcome studied: The outcome studied at each time point was: 
 EDED score  
 Owner subjective assessment of improvement 
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The authors also introduced a binomial outcome (success / failure of 
treatment) “success” measurement. This was based upon the dog 
achieving two things:  
1. An EDED score of < 20, and  
2. An owner subjective assessment of improvement score of ≥ 
+6.  
 
Main findings: 
(relevant to PICO question): 
Please note: in reporting the findings, I have included the phase “+ 
BMP” to each treatment group to improve reader understanding of 
the treatment group structure. The authors of this paper refer 
instead only the groups as ‘alpha-casozepine’ and ‘selegiline’ but it is 
felt that this is misleading. 
 
EDED scores: 
 The average EDED score for both treatment groups 
decreased between visits 1 (day 0) and visit 3 (day 56) 
(alpha-casozepine group + BMP: F(4, 18) = 22.20, P < 0.0001; 
selegiline + BMP: F(4,18) = 26.33, P < 0.0001).  
 At the start of the study (visit one), there was no significant 
difference between the two treatment groups. The average 
EDED scores on visit 1 were: alpha-casozepine + BMP: 25.0; 
selegiline + BMP: 24.2 
 At the end of the study (visit 3, day 56), there was no 
significant difference between the two treatment groups. 
The average EDED scores on visit 3 were: alpha-casozepine + 
BMP: 26.3; selegiline + BMP: 16.6. 
Owner subjective assessment of improvement: 
 The data analysed using an ANOVA statistical test are not 
reported in a clear enough way to precisely define what the 
researchers think they found. 
 The average improvement score of the apha-casozepine + 
BMP group increased from 2.7 on day 14 to 5.3 on day 56. 
 The average improvement score of the selegiline + BMP 
group increased from 3.0 on day 14 to 5.4 on day 56. 
 At the end of the trial (day 56) the improvement score did 
not significantly differ between the two treatment groups 
(Mann-whitney U test, P = 0.73)  
Success / failure measurement: 
 There was no significant association between treatment 
received and proportion of dogs that responded successfully 
to the treatment (χ2 test, d.f. = 1, P = 0.74).  
 The number of successes (failures) in the two groups was: 
alpha-casozepine + BMP: 10 (9); selegiline + BMP: 9 (10). 
Limitations: The study was funded by Ingredia SA (Arras, France). Ingredia is a 
company producing milk products and value-added bioactive 
compounds related to milk. It is not stated whether the funder had 
input into the study design but its authors report that, during data 
collection, only the sponsor knew which dog received which 
treatment during the trial.  
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There was no BMP only treatment group and / or BMP + placebo 
group.  
 
The paper cited by the authors (Pageat, 1995) is in French so it is not 
possible to use this paper to better understand the usage of the 
EDED scale in relation to assessment of selegiline. 
 
The authors do not make clear what they mean by average. Were 
they presenting medians or means?  They do not report any 
measures of variation (e.g. standard deviation, inter-quartile range, 
standard error of the mean). 
 
The authors switch between using parametric and non-parametric 
tests to study aspects of the same data. They do not report any 
information to indicate that they considered the underlying 
distribution of the data.  
 
Statistical output reported for the between treatment group 
pairwise comparisons at visit 1 (day 0) and visit 3 (day 56) is unclear 
as only one P value is reported (P = 0.79) for both results. 
 
Technically, the authors cannot make the claim reported in the EDED 
scores section (that scores decreased between visits one and three 
for each treatment group) because they only appear to have carried 
out an ANOVA. The degrees of freedom indicate that they fitted 5 
time points (presumably physical visits 1-3, and telephone calls 1-2). 
However, no post hoc test has been carried out to identify between 
which two (or more) pairs of time points the significant difference(s) 
arises between. Eyeballing the graphical data suggests that a 
significant difference was most likely between visit 1 and 3, but this 
is complicated by the lack of variation reported. This criticism also 
applies the ANOVA analysed aspect of the owner subjective 
assessment of improvement scores. 
 
The reporting of the ANOVA analysis for the owner subjective 
assessment of improvement scores is not clear enough. It is 
assumed that they are comparing four time points (physical visits 2-
3, telephone visits 1 -2 because of the degrees of freedom reported) 
but they do not include enough information. 
 
The claims that are made throughout the research paper are 
misleading and introduce a potential interpretation bias on the part 
of the reader with limited research methodology knowledge. The 
authors consistently refer to the two groups as alpha-casozepine 
and selegiline, but make limited mention of the fact that these dogs 
all also received a behaviour modification programme, with no 
mention at all in the results or conclusion (there is no discussion 
section). Despite this major confounding variable, the authors make 
statements like: 
“both compounds were equally efficacious” (results), “both products 
were efficient to decrease the EDED score” (abstract), “due to this 
efficacy…. Alpha-casozepine (Zylkene) should be considered an 
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option by the veterinary surgeon for the biological management of 
anxiety” (abstract), etc.  
These claims cannot be made given the lack of an adequate control 
group as each compound could be equally efficacious at having no 
impact on anxiety (i.e. the BMP was the successful component). 
 
3. Kato (2012) 
Population: Healthy adult small-medium (1.4 – 12.6kg) pet dogs that scored as 
‘anxious’ on the Canine Behavioural Assessment & Research 
Questionnaire (C – BARQ).   Both genders were included and a 
variety of ages and breeds.  
 
Dogs were excluded if they: 
 Were pregnant 
 Less than one year of age 
 Had had a medical condition (i.e. not necessarily current) 
 Were a recipient of behavioural therapy or medications 
aimed at treating behavioural problems (i.e. psycho-active 
drugs) 
Sample size: 44 dogs were recruited to the study. 28 dogs completed the study.  
 4 dogs were lost to follow up during the study; the others 
withdrew for reasons unconnected to the trial (health issues 
of the dogs or personal circumstances of the owner). 
Intervention details: The two diet treatments compared for their effects on indices of 
canine anxiety in a crossover, single-blind, single order trial were: 
1. Control diet (Royal Canin Select Skin Care Vets Plan) 
2. Experimental diet containing elevated levels of the amino 
acid tryptophan and alpha-casozepine (Royal Canin Calm Canine) 
 The alpha-casozepine inclusion rate was 1.35g/kg dry matter 
(DM), to provide dogs with a dose of approximately 
20mg/kg/day (the recommended dose for dogs under 15kg). 
 The tryptophan content of the experimental diet was 
3.04g/kg DM (the control diet contained 2.83g/kg DM). 
 The diets were not identical in all other respects. All the 
nutritional components reported differed in inclusion rate. 
 The dogs were retained in their home environment 
throughout the study and fed by their owner (who was 
blinded to the treatment they were feeding their dog). 
The experimental timeline is as follows: 
 The owners of potential canine participants completed a C-
BARQ questionnaire. Dogs that scored as anxious (n = 44) 
were included in the trial. 
 Dogs received the control diet for 8 weeks. They were fed 
twice a day.  Data collection took place in week 7 (see below 
for outcome measures) and comprised completion of the C - 
BARQ questionnaire to assess behavioural indices of anxiety 
and two urine samples collected to assess urinary cortisol 
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levels. One sample was taken in the home environment 
(baseline, unstressed measurement) and one sample was 
taken 2hr post vet clinic visit (the ‘stressed’ measurement). 
 Dogs then received a 1 week wash out period. The diet fed 
during this period is not stated and is assumed to be the 
dog’s normal diet.  
 Dogs then received the experimental diet for 8 weeks. All 
other details are the same as for the control diet phase. 
Further details: 
 The wash out period length was determined by a prior 
preliminary experiment using high-pressure liquid 
chromatography which demonstrated that the dietary 
additives would be entirely removed from the dogs systems 
within one week.  
 Cortisol analysis was carried out in duplicate. 
 Urine collection was carried out at the same point of day to 
reduce the risk of time of day effects on cortisol production.  
Study design: Experimental cross-over trial 
Outcome studied: The outcome measures studied were all potentially relevant to 
answering this PICO. The outcome measures included: 
 Urinary cortisol:creatinine ratio (UCCR) 
- Baseline measurement: taken in the dog’s home 
environment 
- Post-stressor measurement: taken 2hrs post vet 
clinic visit 
 Severity of stranger – directed aggression 
 Severity of owner – directed aggression 
 Severity of stranger – directed fear 
 Severity of non-social fear 
 Level of touch sensitivity 
 
All, bar UCCR, were assessed using specific questions within the C-
BARQ questionnaire. This questionnaire asks owners a series of 
questions to assess each parameter, and owners are asked to score 
their dog on a scale from 0 (no signs of the behavior) to 4 (signs are 
severe). The scores for each parameter’s questions (e.g. for stranger-
directed aggression there are 10 related questions) are then 
averaged, to provide a mean score for that parameter. 
 
The C-BARQ questionnaire is a widely used, validated method of 
assessing canine behavior in a range of ways (not specifically 
anxiety). 
 
Main findings: 
(relevant to PICO question): 
UCCR: 
• Baseline UCCR of the dogs was not significantly different 
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between treatments. 
• Post stressor UCCR was significantly different to baseline 
measurement, irrespective of treatment (i.e. the dogs were stressed 
by the veterinary visit) (P < 0.01). 
• The Mean (±standard error of the mean, S.E.M.) UCCR of the 
dogs post-stressor was significantly lower (P = 0.04) when they were 
being fed the experimental diet (32.17 ± 0.21 x 10-6) than when they 
were being fed the control diet (39.61 ± 0.3-6). 
 
Questionnaire assessment of the dogs’ anxiety-related behaviours: 
• There was a significant reduction in stranger-directed 
aggression when the dogs were being fed the experimental diet (t = 
2.44, d.f. = 15, P = 0.014). The mean (± S.E.M.) scores were: control: 
1.25 (± 0.22); experimental: 0.85 (± 0.20). 
• There was no effect of diet on owner-directed aggression. 
The mean (± S.E.M.) scores were: control: 0.47 (± 0.07); 
experimental: 0.43 (± 0.07). 
• There was a significant reduction in stranger-directed fear 
when the dogs were being fed the experimental diet (t = 3.08, d.f. = 
22, P = 0.014). The mean (± S.E.M.) scores were: control: 1.51 (± 
0.22); experimental: 1.15 (± 0.14). 
• There was a significant reduction in non-social fear when the 
dogs were being fed the experimental diet (t = 2.00, d.f. = 17, P = 
0.031). The mean (± S.E.M.) scores were: control: 1.44 (± 0.22); 
experimental: 1.20 (± 0.23). 
• There was a significant reduction in touch sensitivity when 
the dogs were fed the experimental diet (t = 3.56, d.f. = 25, P < 
0.001). The mean (± S.E.M.) scores were: control: 1.34 (± 0.14); 
experimental: 1.01 (± 0.12). 
Limitations: The study was partially funded by Royal Canin. The authors do not 
state whether Royal Canin had any input into the experimental 
design. 
 
The study was not specifically designed to study the effects of alpha-
casozepine on anxiety. Rather, it was set up to study the effects of a 
commercial diet that contained alpha-casozepine and increased 
levels of tryptophan. Thus, there was a complete confounding 
variable when using this study to address the PICO question. 
 
The diets used were not identical in all other respects, other than 
the dietary additives. This was sufficient for a commercial aim (to 
show the diet was beneficial) but limited interpretation of the 
effects of any specific additive.  
 
The study did not randomise the order in which the dogs received 
the treatments. Therefore, the study is at risk of order effect biases. 
It is not clear why this was not done as the order that the diets was 
presented to the dogs was under the control of the experimenters 
and the experimenters provide no explanation for why this approach 
was taken.  
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The authors refer to preliminary data to establish that dietary 
additives to the diet would be fully eliminated from the body within 
one week, in order to justify the one week washout period. 
However, it is unclear what dietary additives they are referring to as 
the experimental diet containing the additional dietary additive 
(alpha-casozepine) or increased levels of the dietary additive 
tryptophan was presented to all dogs in the second (post wash out 
period) phase of the study.   
 
Cortisol is a non-specific measure of arousal, rather than a specific 
biomarker for stress. Therefore, it is possible that the dogs were 
excited or stimulated by a trip to the vets, rather than fearful. The 
authors fail to determine what the dogs’ normal behavioural 
response is to a trip to the vets. 
 
The C-BARQ questionnaire assessment of the dogs to determine 
which dogs were included in the study provides insufficient detail.   
1. The C-BARQ questionnaire used is not a questionnaire that 
has been validated to anxiety per se. Several of the 
categories are specifically designed to assess fear, but some 
are not. Or particular relevance here is the aggression-
related categories. Not all aggression is derived from 
anxiety.  
2. The definition of an ‘anxious dog’ (i.e. that meets the 
inclusion criteria) was very loosely defined. Dogs were only 
excluded if, on all the questions asked (n = 321), the owner 
scored the dog as a 0 (no sign) to 1 (mild signs observed). 
Thus, a dog could be included if the owner scored it as a 2 
(somewhere between mild and moderate) on just one of the 
questions. 
 
1Assumes mutual exclusivity of the questions. The authors do not 
clarify whether one question assesses more than one parameter 
simultaneously. 
 
 
Appraisal, application and reflection 
 
Three peer reviewed papers were identified that either partially or fully addressed the PICO. Two of these 
studies (Palestrini et al., 2010; Kato et al., 2012) investigated the use of diets with added alpha-casozepine, 
though, in the Kato et al. (2012) study the diet was also supplemented with another compound (tryptophan) 
thought to have anxiolytic properties. The remaining study (Beata et al., 2007) investigated the use of a daily 
capsule of alpha-casozepine. The two studies focused on dietary interventions (Palestrini et al, 2010; Kato et 
al., 2012) used a placebo-controlled study design, whereas Beata et al. (2007) compared alpha-casozepine to 
another intervention (selegiline) that was already used commercially as an anxiolytic. 
 
All of the studies focus on the potential anxiety-reducing effects of alpha-casozepine when administered in 
the medium to long term. Time from baseline measurement to the first and last assessment of anxiety 
ranged from 14-56 days (Beata et al., 2007), c.30-68/69 days (Palestrini et al. 2012) or 7 weeks (one defined 
timepoint) (Kato et al. 2012).  The Palestrini et al. (2010) study also undertook an assessment of the dogs at 
the start of administering the diet (separate to an additional set of baseline measurements taken 
immediately before starting the diet). However, there is insufficient study detail to define the exact details 
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here and the number of days that comprised this phase is uncertain. Furthermore, as no significant 
differences were identified between this and the pre-diet baseline measurements, it is clear that there are no 
studies that found a significant effect of alpha-casozepine on indices of anxiety in the short term. Further, no 
studies were identified that looked at the effects of alpha-casozepine to a dog shortly before (e.g. minutes to 
a few days) exposure to a novel, or intermittent stressor (e.g. fireworks). Thus, there is currently no research 
evidence to support recommending the use of alpha-casozepine to clients seeking a quick acting anxiolytic 
product to alleviate short term stressors in the dog’s immediate or short term future. 
 
All three of the studies that examined the effect of alpha-casozepine administration in the medium-long-term 
of indices of anxiety were problematic in terms of experimental design. Of the studies that looked at the 
effect of alpha-casozepine, the industry-sponsored study by Beata et al. (2007) offered the weakest 
experimental design and the authors appear unaware of this limitation as the conclusions that they draw are 
misleading. Equivalence and / or non-inferiority type studies in which a new treatment is compared to an 
existing treatment are increasingly commonplace in medical research and justified as removing the ethical 
issues of not treating some patients at all (or giving a placebo). Beata et al. (2007) adopt this approach, but 
their study design also includes a behavioural modification programme (BMP) alongside each of the anxiolytic 
products compared. This represents a confounding variable. As a consequence, even though their findings 
appear to indicate that alpha-casozepine has a similar efficacy as selegiline, based on their study design, the 
level of efficacy (from no effect to very effective) cannot be determined for either product as the effect of 
BMP is also unknown.   This problem is compounded by their exclusion criteria as they systematically exclude 
any dogs that have already received BMP. Thus, it is not possible for the authors to justify their conclusions 
by the claim that, prior to starting anxiolytic therapy, these dogs had failed to respond to the BMP. Though 
even this appeal would be sensitive to the effects of time spent implementing a BMP on indices of anxiety 
reduction. Any appeal to the efficacy of alpha-casozepine would require appeal to the wider literature 
demonstrating an effect of selegiline per se on indices of anxiety in the dog and the inherent limitations and 
problems that entails. Thus, this study fails to address adequately the PICO posed in the Knowledge 
Summary. 
 
Of the three studies, the Palestrini et al. (2010) most successfully set up their treatment groups to address 
the PICO. The two diets compared are identical other than the addition of caseinate hydrolysate (the milk 
protein isolate containing alpha-casozepine) and the dogs are not undergoing a behavioural modification 
programme. However, they fail to state the inclusion rate of the caseinate hydrolysate and the dogs were 
allowed to consume the diet on an ad libitum basis so individual dog exposure to the active ingredient was 
variable.  One of the strengths of this study is that they also include a non-anxious group of dogs that are also 
randomly allocated to receive either the experimental or control diets. This potentially allowed them to 
identify whether any behavioural changes observed were due to other, non-anxiety based, properties of 
alpha-casozepine. However, the sample sizes utilised in this study were small to start with (n = 8 per sub-
group), and they took the further, questionable, step at the end of data collection, of retrospectively 
removing from the main analysis, three of the dogs in the anxious group. They fail to report which of the 
treatment groups (experimental versus control diet) these dogs were allocated to and this means that one of 
these subgroups (crucial to answering the PICO) may have had as few as 5 dogs in it. Frequently, the paper 
moves from comparing diet groups (the aim of the study) to comparing the responses of anxious and non-
anxious dogs and, therefore, fails to address the PICO at many points. There is some evidence (cortisol, 
reactivity evaluation form) to suggest the experimental diet reduced anxiety in anxious dogs by the end of 
the study, but most other physiological or behavioural parameters were either not affected by treatment or 
the findings are unreported. Poor data handling and reporting (see limitations) further limit the ability of the 
reader to draw meaningful inferences from the findings of this study. External validity is also questionable: 
with a captive-bred, born, reared and studied population of laboratory beagles and a maximum sample size 
per group of eight dogs (or lower), it is questionable how well any findings could be extrapolated to the pet 
population, with their varying genetic history and life time experiences. 
 
Unfortunately, the final study (Kato et al. 2012) is also problematic in terms of addressing the PICO. In its 
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defence, this industry sponsored study was not set up specifically to study alpha-casozepine but rather the 
effects of feeding a diet containing both alpha-casozepine and tryptophan on longer term indices of anxiety 
in the pet dog. Thus, the confounding variable of these additives to the diet exists for the purpose of the PICO 
but not for the purpose of the original study. However, the treatment diets were still not tightly controlled 
with the two diets varying across many dimensions other than the additives thought to reduce anxiety. Dogs 
were used as their own control, with an eventual sample of 28 dogs. Data handling was better within this 
study with relative homogeneity of the treatment effects observed: of the six outcome measures used, only 
one parameter showed no effect of treatment (owner – directed aggression). The other five parameters 
(urinary cortisol: creatinine ratio, stranger directed aggression, stranger-directed fear, non-social fear, and 
touch sensitivity) were all significantly improved when the dogs were fed the experimental diet. However, 
inclusion criteria for the study was relatively lax. If a dog scored above 1 on any one question out of circa 28 
questions selected from the pre-validated C-BARQ questionnaire for being thought (by the researchers) to be 
potential measures of anxiety in the dog, they were included in the study. The mean values for each dog on 
the control diet suggests that dogs were generally scoring low across categories anyway which suggests that, 
in general these were not necessarily a particularly anxious population of dogs that were studied. 
Furthermore, the experimental design put the findings at a relatively high risk of bias. Despite the authors 
having experimental control over the study population, they chose to undertake an experimental design in 
which all dogs first received the control diet, followed by all dogs receiving the experimental diet. This makes 
the outcome particularly sensitive to order effects as dogs may simply have improved over time. For 
example, the cortisol of the dogs was lower at the second visit to the veterinary clinic. This could be because 
the dog had habituated to the veterinary practice (though the authors point out these dogs visited the vets 
regularly). Alternatively, if owners chose to participate in a trial testing diets aimed at reducing anxiety, this 
might alert them to the need to other information that might be used to reduce anxiety in their dogs. 
Furthermore, the researchers refer to a wash out period of 1 week between trials to ensure that additives 
have been removed, yet it is not clear what additives they are referring to as the ones in question are only 
included in the second phase. 
 
In summary, whilst there is some evidence (through a shared direction of effect where a significant effect 
exists) across the studies that alpha-casozepine may have a clinically beneficial effect in reducing canine 
anxiety in the medium to longer term, the current evidence is weak and there is a need for good quality, 
placebo-controlled, randomised clinical trials that specifically address this compound for common anxiety-
causing scenarios that this biomolecule may be promoted as a potential solution for. 
 
Methodology Section 
 
Search Strategy 
Databases searched and dates 
covered: 
Pubmed (1900 – 2017); Web of Science (1970 –2017); CAB 
Abstracts (1983 – 2016) 
Search terms: (dog OR dogs OR canine OR bitch* OR canid OR puppy OR puppies) 
AND (“alpha casozepine” OR alfa1-casozepine OR alpha-casozepine 
OR casein OR “milk protein” OR zylkene OR milk) AND (anxiety OR 
anxious OR fear OR fearful OR stress OR stressed OR stressful OR 
panic OR phobi*) 
 
Dates searches performed: 11th July 2017 
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Exclusion / Inclusion Criteria 
Exclusion: Pre-defined exclusion criteria:  non English language, popular press 
articles 
Inclusion: Any comparative (control group utilised) study in which the effect 
of alpha-casozepine on anxiety (or similar) in dogs was studied. 
 
Search Outcome 
Database Number 
of results 
Excluded – did 
not answer 
PICO question 
Excluded – 
not English 
language 
Excluded – 
conference 
abstract only 
Excluded – 
duplicates 
Total 
relevant 
papers 
NCBI PubMed 22 22 0 0 0 0 
Thomson 
Reuters Web 
of Science 
33 30 1 0 0 2 
CAB Abstracts 46 42 1 1 1 2 
Total relevant papers when duplicates removed 3 
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